These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 31405660)
1. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus. Farhan SS; Hussain SA Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660 [TBL] [Abstract][Full Text] [Related]
2. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649 [TBL] [Abstract][Full Text] [Related]
3. Serum AGEs and sRAGE levels are not related to vascular complications in patients with prediabetes. Gateva AT; Assyov YS; Tsakova AD; Kamenov ZA Diabetes Metab Syndr; 2019; 13(2):1005-1010. PubMed ID: 31336435 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684 [TBL] [Abstract][Full Text] [Related]
6. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Prasad K Mol Cell Biochem; 2019 Jan; 451(1-2):139-144. PubMed ID: 29961210 [TBL] [Abstract][Full Text] [Related]
7. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Kajikawa M; Nakashima A; Fujimura N; Maruhashi T; Iwamoto Y; Iwamoto A; Matsumoto T; Oda N; Hidaka T; Kihara Y; Chayama K; Goto C; Aibara Y; Noma K; Takeuchi M; Matsui T; Yamagishi S; Higashi Y Diabetes Care; 2015 Jan; 38(1):119-25. PubMed ID: 25336748 [TBL] [Abstract][Full Text] [Related]
8. Serum advanced glycation end-products and receptors as prognostic biomarkers in diabetics undergoing coronary artery stent implantation. Shen Y; Pu LJ; Lu L; Zhang Q; Zhang RY; Shen WF Can J Cardiol; 2012; 28(6):737-43. PubMed ID: 23073352 [TBL] [Abstract][Full Text] [Related]
9. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247 [TBL] [Abstract][Full Text] [Related]
10. Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Wannamethee SG; Welsh P; Papacosta O; Ellins EA; Halcox JPJ; Whincup PH; Sattar N Atherosclerosis; 2017 Sep; 264():36-43. PubMed ID: 28759844 [TBL] [Abstract][Full Text] [Related]
11. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis. Ruggeri RM; Barbalace MC; Cristani MT; Alibrandi A; Giovinazzo S; Giuffrida G; Trimarchi F; Cannavò S; Campennì A J Endocrinol Invest; 2020 Sep; 43(9):1337-1342. PubMed ID: 32232775 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381 [TBL] [Abstract][Full Text] [Related]
13. Glycated albumin and the risk of chronic kidney disease in subjects with Type 2 Diabetes: A study in North Indian Population. Raghav A; Ahmad J; Noor S; Alam K; Mishra BK Diabetes Metab Syndr; 2018 May; 12(3):381-385. PubMed ID: 29396252 [TBL] [Abstract][Full Text] [Related]
14. Type 1 diabetes and hearing loss: Audiometric assessment and measurement of circulating levels of soluble receptor for advanced glycation end products. Al-Sofiani M; MacLeod S; Ghanim H; Stecker N; Hall J; Lippes H Diabetes Metab Res Rev; 2020 Sep; 36(6):e3312. PubMed ID: 32191386 [TBL] [Abstract][Full Text] [Related]
15. Poorly controlled type 2 diabetes with no progression of diabetes-related complications and low levels of advanced glycation end products: A Case report. Nakamura T; Tsujimoto T; Yasuda K; Chujo D; Ohsugi M; Tanabe A; Ueki K; Kajio H Medicine (Baltimore); 2019 Jul; 98(30):e16573. PubMed ID: 31348288 [TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839 [TBL] [Abstract][Full Text] [Related]
17. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals. Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256 [TBL] [Abstract][Full Text] [Related]
18. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Sato A; Imaizumi T Diabetes Metab Res Rev; 2007 Jul; 23(5):368-71. PubMed ID: 17024691 [TBL] [Abstract][Full Text] [Related]
19. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468 [TBL] [Abstract][Full Text] [Related]
20. Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients. Jafari Nakhjavani MR; Jafarpour M; Ghorbanihaghjo A; Abedi Azar S; Malek Mahdavi A Mod Rheumatol; 2019 Nov; 29(6):943-948. PubMed ID: 30474471 [No Abstract] [Full Text] [Related] [Next] [New Search]